IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) will participate in two investor relations events in November 2025: a Citi 2025 SMID Cap Biopharma Call Series fireside chat on Nov 6, 2025 at 12:00 PM ET, and a Jefferies Global Healthcare Conference fireside chat in London on Nov 18, 2025 at 1:00 PM GMT / 8:00 AM ET.

Both sessions feature CEO Yujiro S. Hata in discussion with industry analysts. Live audio webcasts will be available at the IDEAYA Investors/Events page and/or via the conference hosts, with replay access for 30 days where permitted.

News Market Reaction – IDYA

+10.93%

63 alerts

+10.93% News Effect

+5.6% Peak in 5 hr 43 min

+$280M Valuation Impact

$2.84B Market Cap

1.3x Rel. Volume

On the day this news was published, IDYA gained 10.93%, reflecting a significant positive market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 63 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $280M to the company's valuation, bringing the market cap to $2.84B at that time.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.

Citi's 2025 SMID Cap Biopharma Call Series
Thursday, November 6^th, 2025 at 12:00 PM ET

• Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst

Jefferies Global Healthcare Conference in London
Tuesday, November 18^th, 2025 at 1:00 PM GMT | 8:00 AM ET

• Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

A live audio webcast of the conference events, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-november-2025-investor-relations-events-302594206.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

When will IDEAYA (NASDAQ: IDYA) present at the Citi SMID Cap Biopharma Call Series in 2025?

IDEAYA will present on Thursday, November 6, 2025 at 12:00 PM ET as part of the Citi SMID Cap Biopharma Call Series.

What time is IDEAYA (IDYA) scheduled to speak at the Jefferies Global Healthcare Conference in London?

IDEAYA is scheduled for Tuesday, November 18, 2025 at 1:00 PM GMT (8:00 AM ET) at the Jefferies conference in London.

Who will represent IDEAYA (IDYA) in the November 2025 investor events?

CEO Yujiro S. Hata will participate in fireside chats at both November 2025 investor events.

Where can investors access the IDEAYA (IDYA) live webcasts for the November 2025 events?

Live audio webcasts will be available at the IDEAYA Investors/Events page (https://ir.ideayabio.com/events) and/or through the conference hosts where permitted.

Will IDEAYA (IDYA) provide replays of the November 2025 investor event webcasts?

Yes. Replay of available webcasts will be accessible for 30 days following the live event, subject to conference host permissions.

What topics will IDEAYA (IDYA) cover during the November 2025 fireside chats?

The announcements state IDEAYA will participate in fireside chats featuring company updates and discussion with analysts; specific topics will be disclosed during the live sessions.